Tumor-homing glycol chitosan-based optical/PET dual imaging nanoprobe for cancer diagnosis.

Imaging techniques including computed tomography, magnetic resonance imaging, and positron emission tomography (PET) offer many potential benefits to diagnosis and treatment of cancers. Each method has its own strong and weak points. Therefore, multimodal imaging techniques have been highlighted as an alternative method for overcoming the limitations of each respective imaging method. In this study, we fabricated PET/optical activatable imaging probe based on glycol chitosan nanoparticles (CNPs) for multimodal imaging. To prepare the dual PET/optical probes based on CNPs, both (64)Cu radiolabeled DOTA complex and activatable matrix metalloproteinase (MMP)-sensitive peptide were chemically conjugated onto azide-functionalized CNPs via bio-orthogonal click chemistry, which was a reaction between azide group and dibenzyl cyclooctyne. The PET/optical activatable imaging probes were visualized by PET and optical imaging system. Biodistribution of probes and activity of MMP were successfully measured in tumor-bearing mice.

[1]  Kwangmeyung Kim,et al.  Non-invasive optical imaging of cathepsin B with activatable fluorogenic nanoprobes in various metastatic models. , 2014, Biomaterials.

[2]  Ick Chan Kwon,et al.  Facile method to radiolabel glycol chitosan nanoparticles with (64)Cu via copper-free click chemistry for MicroPET imaging. , 2013, Molecular pharmaceutics.

[3]  Brian C. Wilson,et al.  Inherently Multimodal Nanoparticle-Driven Tracking and Real-Time Delineation of Orthotopic Prostate Tumors and Micrometastases , 2013, ACS nano.

[4]  R. Mariani-Costantini.  Diagnosis: Breast cancer screening in rural African communities , 2013, Nature Reviews Clinical Oncology.

[5]  Kwangmeyung Kim,et al.  Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. , 2012, Angewandte Chemie.

[6]  V. Muzykantov,et al.  Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.

[7]  Kwangmeyung Kim,et al.  Effect of the stability and deformability of self-assembled glycol chitosan nanoparticles on tumor-targeting efficiency. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Xiaoyuan Chen,et al.  Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using (64)Cu-DOTA-VEGF(121) and microPET. , 2012, Nuclear medicine and biology.

[9]  Michael J Welch,et al.  Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. , 2012, Bioconjugate chemistry.

[10]  Ick Chan Kwon,et al.  Multifunctional nanoparticles for multimodal imaging and theragnosis. , 2012, Chemical Society reviews.

[11]  Kwangmeyung Kim,et al.  Cathepsin B-sensitive nanoprobe for in vivo tumor diagnosis , 2011 .

[12]  Han-Sung Kim,et al.  Tumor-targeting gold particles for dual computed tomography/optical cancer imaging. , 2011, Angewandte Chemie.

[13]  Marina N. Nikiforova,et al.  Molecular genetics and diagnosis of thyroid cancer , 2011, Nature Reviews Endocrinology.

[14]  Theresa M Reineke,et al.  Theranostics: combining imaging and therapy. , 2011, Bioconjugate chemistry.

[15]  Ick Chan Kwon,et al.  Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. , 2011, Biomaterials.

[16]  Carolyn R Bertozzi,et al.  Bringing chemistry to life , 2011, Nature Methods.

[17]  Cédric Louis,et al.  Biodistribution study of nanometric hybrid gadolinium oxide particles as a multimodal SPECT/MR/optical imaging and theragnostic agent. , 2011, Bioconjugate chemistry.

[18]  Kwangmeyung Kim,et al.  Nanoprobes for biomedical imaging in living systems , 2011 .

[19]  Kwangmeyung Kim,et al.  Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe. , 2011, Bioconjugate chemistry.

[20]  M. Socinski,et al.  Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. S. Moses,et al.  Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.

[22]  R. Weissleder,et al.  Hybrid PET-optical imaging using targeted probes , 2010, Proceedings of the National Academy of Sciences.

[23]  C. Bertozzi,et al.  Cu-free click cycloaddition reactions in chemical biology. , 2010, Chemical Society reviews.

[24]  M. Han,et al.  Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. , 2010, Bioconjugate chemistry.

[25]  C. Ahn,et al.  Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. , 2009, Nano letters.

[26]  Hao Hong,et al.  Molecular imaging and therapy of cancer with radiolabeled nanoparticles. , 2009, Nano today.

[27]  Molly S. Shoichet,et al.  Organic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer , 2009 .

[28]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[29]  Shuang Liu.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. , 2008, Advanced drug delivery reviews.

[30]  J. Willmann,et al.  Molecular imaging in drug development , 2008, Nature Reviews Drug Discovery.

[31]  Yasuyoshi Watanabe,et al.  [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.

[32]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[33]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[34]  R. Ala-aho,et al.  Matrix metalloproteinases as therapeutic targets in cancer. , 2005, Current cancer drug targets.

[35]  Sanjiv S Gambhir,et al.  FDG-PET and beyond: molecular breast cancer imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Ick Chan Kwon,et al.  Physicochemical Characteristics of Self-Assembled Nanoparticles Based on Glycol Chitosan Bearing 5β-Cholanic Acid , 2003 .

[37]  S. Gambhir.  Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[38]  Ralph Weissleder,et al.  Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. , 2002, Bioconjugate chemistry.

[39]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[40]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[41]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[42]  Ralph Weissleder,et al.  In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.

[43]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[44]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[45]  P. Laird.  Cancer epigenetics , 2005 .

[46]  S. Zucker,et al.  Role of matrix metalloproteinases (MMPs) in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[47]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.